Inventaire - your friends and communities are your best library

Ziprasidone versus other atypical antipsychotics for schizophrenia

author

Werner Kissling

Stefan Leucht

Christine Rummel-Kluge

Katja Komossa

published in: Cochrane Database of Systematic Reviews

date of publication: 2009

language: English

main subject: schizophrenia

Cites articles 131

Date

Title

Authors

2014-03-15

Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study

Jörg Daumann, Euphrosyne Gouzoulis-Mayfrank
2012-02-06

Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data

Shitij Kapur, Dragana Bugarski-Kirola
2012-02-07

Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial.

Haya Ascher-Svanum
2012-05-23

Treatment of depression in first episode of schizophrenia: results from EUFEST.

Joseph Peuskens, René S. Kahn, Marek Jarema, Janusz Rybakowski
2012-03-01

Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version)
2011-11-17

SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: data from the CATIE study

Karolina Aberg, Joseph L. McClay, Patrick F. Sullivan
2011-10-01

Predicting psychiatric hospital admission among adults with schizophrenia

Haya Ascher-Svanum, Mark Olfson, Steven C Marcus
2011-08-31

Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial
2011-08-27

Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine
2011-07-01

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

Jan Libiger, Eske M Derks, Istvan Bitter, René S. Kahn
2011-05-10

Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study

T. Scott Stroup, Theo C Manschreck, Paul Stuart Appelbaum, Jeffrey Lieberman
2011-03-04

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia

Manjula Schou
2011-02-21

The association between weight change and symptom reduction in the CATIE schizophrenia trial

Robert A. Rosenheck, Donald C Goff, Henry Nasrallah, Jeffrey Lieberman
2011-02-01

Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial
2011-03-01

Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone

Leonardo Baldaçara, Marsal Sanches
2011-02

The Role of the Family and Improvement in Treatment Maintenance, Adherence, and Outcome for Schizophrenia
2011-08-26

Substance use and schizophrenia: adverse correlates in the CATIE study sample.

Robert A. Rosenheck
2011-10-14

Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study

Haya Ascher-Svanum
2011-02-24

Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample
2011-06-01

Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial

Anita Riecher-Rössler
2011-01-05

Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study

T. Scott Stroup, Kim Coley, Jeffrey Lieberman
2011-12-06

Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial
2011-09

P.3.c.054 Crossover comparison of serum glycemia variability of intramuscular forms of antipsychotics: aripiprazole, olanzapine and ziprasidone
2010-09-21

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia

Robert A. Rosenheck, Jeffrey Lieberman
2010-08-10

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia

Delwyn Miller, T. Scott Stroup, Jeffrey Lieberman, Robert A. Rosenheck
2010-03-24

Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone

Tore Wentzel-Larsen
2010-01-01

A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial

Delwyn Miller, T. Scott Stroup, Kari E North, Patrick F Sullivan, Jeffrey Lieberman
2010-06-10

Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis

Roger S McIntyre
2010-03-03

Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).

Eske M Derks, Wulf Rössler, René S. Kahn
2010-09-15

Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia
2010-06-29

Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone
2010-11-01

Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

John M. Kane, Ralph B. D'Agostino

Article - wd:Q24240260

Welcome to Inventaire

the library of your friends and communities

learn more